BACKGROUND AND OBJECTIVES: ABO-incompatible kidney transplant recipients may have a higher incidence of BK virus allograft nephropathy (BKVAN) compared with ABO-compatible recipients. It is unclear whether HLA-incompatible recipients share this risk or whether this phenomenon is unique to ABO-incompatible recipients. DESIGN, SETTING, PARTICIPATION, MEASUREMENTS: This study analyzed adult incompatible kidney transplant recipients from 1998 to 2010 (62 ABO-incompatible and 221 HLA-incompatible) and identified patients in whom BKVAN was diagnosed by biopsy (per protocol or for cause). This was a retrospective analysis of a prospectively maintained database that compared BKVAN incidence and outcomes between ABO- and HLA-incompatible recipients, respectively. BKVAN link to rejection and graft accommodation phenotype were also explored. The Johns Hopkins Institutional Review Board approved this study. RESULTS: Risk for BKVAN was greater among ABO-incompatible than HLA-incompatible patients (17.7% versus 5.9%; P=0.008). Of BKVAN cases, 42% were subclinical, diagnosed by protocol biopsy. ABO-incompatibility and age were independent predictors for BKVAN on logistic regression. C4d deposition without histologic features of glomerulitis and capillaritis (graft accommodation-like phenotype) on 1-year biopsies of ABO-incompatible patients with and without BKVAN was 40% and 75.8%, respectively (P=0.04). Death-censored graft survival (91%) and serum creatinine level among surviving kidneys (1.8 mg/dl) were identical in ABO- and HLA-incompatible patients with BKVAN (median, 1399 and 1017 days after transplantation, respectively). CONCLUSIONS: ABO-incompatible kidney recipients are at greater risk for BKVAN than HLA-incompatible kidney recipients. ABO-incompatible recipients not showing the typical graft accommodation-like phenotype may be at heightened risk for BKVAN, but this observation requires replication among other groups.
BACKGROUND AND OBJECTIVES:ABO-incompatible kidney transplant recipients may have a higher incidence of BK virus allograft nephropathy (BKVAN) compared with ABO-compatible recipients. It is unclear whether HLA-incompatible recipients share this risk or whether this phenomenon is unique to ABO-incompatible recipients. DESIGN, SETTING, PARTICIPATION, MEASUREMENTS: This study analyzed adult incompatible kidney transplant recipients from 1998 to 2010 (62 ABO-incompatible and 221 HLA-incompatible) and identified patients in whom BKVAN was diagnosed by biopsy (per protocol or for cause). This was a retrospective analysis of a prospectively maintained database that compared BKVAN incidence and outcomes between ABO- and HLA-incompatible recipients, respectively. BKVAN link to rejection and graft accommodation phenotype were also explored. The Johns Hopkins Institutional Review Board approved this study. RESULTS: Risk for BKVAN was greater among ABO-incompatible than HLA-incompatible patients (17.7% versus 5.9%; P=0.008). Of BKVAN cases, 42% were subclinical, diagnosed by protocol biopsy. ABO-incompatibility and age were independent predictors for BKVAN on logistic regression. C4d deposition without histologic features of glomerulitis and capillaritis (graft accommodation-like phenotype) on 1-year biopsies of ABO-incompatible patients with and without BKVAN was 40% and 75.8%, respectively (P=0.04). Death-censored graft survival (91%) and serum creatinine level among surviving kidneys (1.8 mg/dl) were identical in ABO- and HLA-incompatible patients with BKVAN (median, 1399 and 1017 days after transplantation, respectively). CONCLUSIONS:ABO-incompatible kidney recipients are at greater risk for BKVAN than HLA-incompatible kidney recipients. ABO-incompatible recipients not showing the typical graft accommodation-like phenotype may be at heightened risk for BKVAN, but this observation requires replication among other groups.
Authors: Christopher J Sonnenday; Daniel S Warren; Mathew Cooper; Milagros Samaniego; Mark Haas; Karen E King; R Sue Shirey; Christopher E Simpkins; Robert A Montgomery Journal: Am J Transplant Date: 2004-08 Impact factor: 8.086
Authors: R A Montgomery; A A Zachary; L C Racusen; M S Leffell; K E King; J Burdick; W R Maley; L E Ratner Journal: Transplantation Date: 2000-09-27 Impact factor: 4.939
Authors: Cinthia B Drachenberg; John C Papadimitriou; Hans H Hirsch; Ravinder Wali; Clinton Crowder; Joseph Nogueira; Charles B Cangro; Susan Mendley; Ayesa Mian; Emilio Ramos Journal: Am J Transplant Date: 2004-12 Impact factor: 8.086
Authors: Christopher K Buehrig; Donna J Lager; Mark D Stegall; Michelle A Kreps; Walter K Kremers; James M Gloor; Thomas R Schwab; Jorge A Velosa; Mary E Fidler; Timothy S Larson; Matthew D Griffin Journal: Kidney Int Date: 2003-08 Impact factor: 10.612
Authors: Andrea A Zachary; Robert A Montgomery; Lloyd E Ratner; Millie Samaniego-Picota; Mark Haas; Dessislava Kopchaliiska; Mary S Leffell Journal: Transplantation Date: 2003-11-27 Impact factor: 4.939
Authors: Y Itabashi; K Sakai; T Kawamura; Y Hyodo; M Muramatsu; K Arai; A Aikawa; S Mizuiri; T Ohara; C Hasegawa; Y Ishikawa; A Hasegawa Journal: Clin Transplant Date: 2004 Impact factor: 2.863
Authors: Volker Nickeleit; Harsharan K Singh; Parmjeet Randhawa; Cinthia B Drachenberg; Ramneesh Bhatnagar; Erika Bracamonte; Anthony Chang; W James Chon; Darshana Dadhania; Vicki G Davis; Helmut Hopfer; Michael J Mihatsch; John C Papadimitriou; Stefan Schaub; Michael B Stokes; Mohammad F Tungekar; Surya V Seshan Journal: J Am Soc Nephrol Date: 2017-12-26 Impact factor: 10.121
Authors: K Teutsch; F Schweitzer; E Knops; R Kaiser; H Pfister; J Verheyen; H Göbel; T Cingöz; V Di Cristanziano Journal: Med Microbiol Immunol Date: 2015-03-07 Impact factor: 3.402
Authors: Harsharan K Singh; Howard Reisner; Vimal K Derebail; Tomasz Kozlowski; Volker Nickeleit Journal: Transplantation Date: 2015-03 Impact factor: 4.939
Authors: Madelon van Agteren; Willem Weimar; Annelies E de Weerd; Peter A W Te Boekhorst; Jan N M Ijzermans; Jaqueline van de Wetering; Michiel G H Betjes Journal: J Transplant Date: 2014-02-06
Authors: Johannes Jacobi; Antonina Prignitz; Maike Büttner; Klaus Korn; Alexander Weidemann; Karl F Hilgers; Katharina Heller; Joachim Velden; Antje Knöll; Bernd Wullich; Christoph May; Kai-Uwe Eckardt; Kerstin U Amann Journal: BMC Nephrol Date: 2013-10-02 Impact factor: 2.388